+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: Opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used



The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: Opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used



Neuropharmacology 39(6): 1053-1063



This study investigated, using microdialysis in freely-moving rats, the role of serotonin (5-HT) and 5-HT(2) receptor subtypes in the enhancement of striatal dopamine (DA) release induced by various doses of haloperidol. The subcutaneous injection of 0.01, 0.1 or 1 mg/kg haloperidol dose-dependently increased DA outflow (160, 219 and 230% of baseline, respectively). The effect of 0.01 mg/kg haloperidol was, respectively, potentiated by the 5-HT uptake inhibitor citalopram (1 mg/kg, s.c.; +35%) and reduced by the 5-HT(1A) receptor agonist 8-OH-DPAT (0.025 mg/kg, s.c.; -32%). Also, it was reduced by the 5-HT(2A) antagonist SR 46349B (0.5 mg/kg, s.c. ; -40%) or by the 5-HT(2A/2B/2C) antagonist ritanserin (1.25 mg/kg, i.p.; -34%), and potentiated by the 5-HT(2B/2C) antagonist SB 206553 (5 mg/kg, i.p; +78%). Further, only this latter compound significantly modified basal dopamine release by itself (+26%). Dopamine released by 0.1 mg/kg haloperidol was enhanced (+100%) by citalopram, decreased (-61%) by SR 4634B, but unaltered by SB 206553. Finally, none of the compounds used were able to modify the enhancement of dopamine release induced by 1 mg/kg haloperidol. These results show that central 5-HT(2A) and 5-HT(2C) receptors exert an opposite (respectively excitatory and inhibitory) influence on DA release. Moreover, they suggest that the 5-HT(2A)-dependent modulation depends on the degree of central DA receptor blockade.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011497335

Download citation: RISBibTeXText

PMID: 10727716

DOI: 10.1016/s0028-3908(99)00193-8


Related references

Opposite role of central 5-HT2A and 5-HT2C receptor subtypes in the control of haloperidol-induced release of dopamine in the rat striatum. Society for Neuroscience Abstracts 24(1-2): 108, 1998

Role of striatal 5-HT2A and 5-HT2C receptor subtypes in the control of dopamine release in the rat striatum. Society for Neuroscience Abstracts 25(1-2): 2213, 1999

Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat. Psychopharmacology 172(1): 100-107, 2003

5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26(3): 311-324, 2002

The alpha2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: Role of serotonergic mechanisms. Neuropsychopharmacology 28(5): 872-879, 2003

Opposite effects of low versus high dose haloperidol treatments on spontaneous and apomorphine induced motor behavior: evidence that at a very low dose haloperidol acts as an indirect dopamine agonist. Behavioural Brain Research 229(1): 153-159, 2012

5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Research 947(2): 157-165, 30 August, 2002

Effect of AC - 260186, a 5 - HT2A/2C receptor antagonist, on haloperidol - induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 891 16, 2003

5-HT2c receptor antagonists, but not a 5-HT2A or 5-HT2B receptor antagonist, attenuate haloperidol-induced catalepsy in rat. British Journal of Pharmacology 125(PROC Suppl. ): 65P, 1998

TYROSINE DEPLETION AUGMENTS HALOPERIDOL - INDUCED CATALEPSY AND ATTENUATES HALOPERIDOL - INDUCED DOPAMINE RELEASE IN THE STRIATUM OF THE RAT As MEASURED BY in vivo MICRODIALYSIS. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 536 3, 2002

Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge. Brain Research 484(1-2): 389-392, 1989

M100907, a 5-HT2A receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex, but inhibits that in the nucleus accumbens. Society for Neuroscience Abstracts 26(1-2): Abstract No -143 15, 2000

Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology 200(4): 487-496, 2008

Effect of W-7 or dantrolene on haloperidol-induced changes in evoked dopamine release from striatal slices of rats. Neurosciences 21(Suppl. 2): P101-P104, 1995

The role of striatal glutamatergic system in haloperidol-induced dopamine receptor supersensitivity and effects of monosialoganglioside GM1. Pharmacology, Biochemistry, and Behavior 58(4): 903-907, 1998